Salt compound

Abstract

A salt compound, and methods for mitigating neurodegeneration, effecting, neuroprotection and/or effecting cognition enhancement in a subject using the salt compound are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic salt compound comprising, a nitrate ester.

1 . The maleate salt of the compound 
       
         
           
           
               
               
           
         
       
     
     
         2 . A pharmaceutical composition comprising the maleate salt of the compound 
       
         
           
           
               
               
           
         
       
       together with a pharmaceutically acceptable diluent or carrier. 
     
     
         3 . A dry tablet composition comprising the maleate salt of the compound 
       
         
           
           
               
               
           
         
       
       and a pharmaceutically acceptable diluent or carrier. 
     
     
         4 . The dry tablet of  claim 3 , formulated for oral administration. 
     
     
         5 . A method for inhibiting neurodegeneration, or effecting neuroprotection in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition of  claim 1 , such that said neurodegeneration is inhibited or said neuroprotection is effected. 
     
     
         6 . The method of  claim 5 , wherein administering the therapeutic compound to said subject modulates levels of cyclic nucleotide cGMP and/or cAMP. 
     
     
         7 . The method of  claim 5 , wherein said neurodegeneration or said neuroprotection is associated with a condition selected from the group consisting of stroke, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced dementia, epilepsy, alcoholism, alcohol withdrawal, drug-induced seizure, viral/bacterial/fever-induced seizure, trauma to the head, hypoglycemia, hypoxia, myocardial infarction, cerebral vascular occlusion, cerebral vascular hemorrhage, hemorrhage, an environmental excitotoxin, dementia, trauma, drug-induced brain damage, and aging. 
     
     
         8 . The method of  claim 5 , wherein said neurodegeneration or said neuroprotection is associated with dementia. 
     
     
         9 . The method of  claim 5 , wherein said neurodegeneration or said neuroprotection is associated with Alzheimer's disease. 
     
     
         10 . The method of  claim 5 , wherein said composition inhibits dementia. 
     
     
         11 . The method of  claim 5 , wherein said composition inhibits Alzheimer's disease. 
     
     
         12 . A method for effecting cognition enhancement in a subject in need thereof comprising administering to said subject an effective amount a composition of  claim 1 . 
     
     
         13 . A method for mitigating cerebral damage due to ischemia in a subject in need thereof comprising administering to said subject an effective amount of a composition of  claim 1 , such that cerebral damage is mitigated. 
     
     
         14 . The method of  claim 5 , wherein said composition is administered orally. 
     
     
         15 . A method for inhibiting neurodegeneration, or effecting neuroprotection in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition of  claim 2 , such that said neurodegeneration is inhibited or said neuroprotection is effected. 
     
     
         16 . A method for inhibiting neurodegeneration, or effecting neuroprotection in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition of  claim 3 , such that said neurodegeneration is inhibited or said neuroprotection is effected. 
     
     
         17 . A method for inhibiting neurodegeneration, or effecting neuroprotection in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition of  claim 4 , such that said neurodegeneration is inhibited or said neuroprotection is effected. 
     
     
         18 . The method of  claim 12 , wherein said composition is administered orally. 
     
     
         19 . The method of  claim 13 , wherein said composition is administered orally. 
     
     
         20 . The maleate salt of  claim 1 , having the XRPD graphic scan of  FIG. 1 .